EQS-News: CompuGroup Medical appoints Prof. Dr. Daniel Gotthardt as new CEO
|
EQS-News: CompuGroup Medical SE & Co. KGaA
/ Key word(s): Personnel
CompuGroup Medical appoints Prof. Dr. Daniel Gotthardt as new CEO Koblenz. CompuGroup Medical announced today that the Administrative Board appoints the company founder’s son, Prof. (apl.) Dr. med. Daniel Gotthardt, as CEO of CGM effective as of September 1, 2024. The current CEO Michael Rauch will leave the company in the best mutual agreement to pursue new professional challenges outside of CGM. Michael Rauch joined as CFO in August 2019, was then additionally appointed as Spokesman for the Managing Directors in June 2022, and took over the role as CEO in May 2023. He handed over the role as CFO to Daniela Hommel in February 2024. After studying medicine in Heidelberg and completing his doctorate at the Max Planck Institute for medical research and at the Imperial College in London, Daniel Gotthardt worked at the University Clinic Heidelberg for 13 years, most recently as managing senior physician. He was managing director of Mediteo GmbH and the sole board member of Gotthardt Healthgroup AG and XLHealth AG. Since the beginning of 2023, Daniel Gotthardt is Senior Vice President and Chief Medical Officer of CGM. In addition, he has been a member of the Supervisory Board of the former CompuGROUP Holding AG respectively CompuGroup Medical SE since 2003, and was appointed as member of the Administrative Board of CompuGroup Medical Management SE in 2020. Frank Gotthardt, company founder and Chairman of the Administrative Board, comments: “Over the past five years, Michael Rauch has loyally placed his international management experience and his enormous work energy surplus at the service of CGM and its shareholders. With a sustainable focus on free cash flow, he increased organic growth and total revenues by around EUR 500 million to EUR 1.19 billion. I would like to thank him warmly on behalf of the entire Administrative Board for the excellent cooperation and wish him all the very best for his future. With my son Daniel, a medical doctor is now taking the role as CEO for the first time in the company's history, which underlines CGM's clear thematic focus and relentless customer orientation. In addition, he has demonstrated his entrepreneurial skills and visionary expertise in various positions in the crucial future fields of modern cloud systems, data-based solutions and Artificial Intelligence applications in recent years.” Daniel Gotthardt adds: “Medical knowledge is developing exponentially, but at the same time doctors, pharmacists and the many helping hands have less time for each individual patient. As CGM, our most important task is to be a reliable and at the same time innovative partner for our customers in this demanding situation. Data-based and AI-powered solutions open up a new dimension in this context. As CEO, my focus will be on the strengths that are the basis for CGM's success – unwavering customer orientation, operational excellence as well as the consistent focus on a connected and patient-centered healthcare system. For nobody should suffer or die because at some point medical information was missing.”
31.07.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS News - a service of EQS Group AG. |
| Language: | English |
| Company: | CompuGroup Medical SE & Co. KGaA |
| Maria Trost 21 | |
| 56070 Koblenz | |
| Germany | |
| Phone: | +49 (0)160 3630362 |
| Fax: | +49 (0)261 8000 3200 |
| E-mail: | investor@cgm.com |
| Internet: | www.cgm.com |
| ISIN: | DE000A288904 |
| WKN: | A28890 |
| Indices: | SDAX, TecDAX |
| Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
| EQS News ID: | 1958527 |
| End of News | EQS News Service |
|
|
1958527 31.07.2024 CET/CEST
Boersengefluester.de (BGFL) provides an overview of the key figures on sales, earnings, cash flow and dividends to help you better assess the fundamental development of the respective companies. All information is entered manually in our database - the source is the respective annual reports. All estimates for future figures are provided by BGFL.
| The most important financial data at a glance | ||||||||
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026e | ||
| Sales1 | 837,26 | 1.025,32 | 1.129,74 | 1.187,66 | 1.153,99 | 1.188,00 | 0,00 | |
| EBITDA1,2 | 197,48 | 213,39 | 216,35 | 229,76 | 218,74 | 0,00 | 0,00 | |
| EBITDA-Margin3 | 23,59 | 20,81 | 19,15 | 19,35 | 18,96 | 0,00 | 0,00 | |
| EBIT1,4 | 121,77 | 102,68 | 104,03 | 98,00 | 107,09 | 0,00 | 0,00 | |
| EBIT-Margin5 | 14,54 | 10,01 | 9,21 | 8,25 | 9,28 | 0,00 | 0,00 | |
| Net Profit (Loss)1 | 73,42 | 69,03 | 74,12 | 46,87 | 34,76 | 0,00 | 0,00 | |
| Net-Margin6 | 8,77 | 6,73 | 6,56 | 3,95 | 3,01 | 0,00 | 0,00 | |
| Cashflow1,7 | 149,93 | 165,27 | 145,03 | 179,53 | 128,88 | 0,00 | 0,00 | |
| Earnings per share8 | 1,40 | 1,30 | 1,40 | 0,88 | 0,66 | 1,07 | 1,22 | |
| Dividend per share8 | 0,50 | 0,50 | 0,50 | 1,00 | 0,05 | 0,50 | 0,50 | |
1 in Mio. Euro; 2 EBITDA = Earnings before interest, taxes, depreciation and amortisation; 3 EBITDA in relation to sales; 4 EBIT = Earnings before interest and taxes; 5 EBIT in relation to sales; 6 Net profit (-loss) in relation to sales; 7 Cashflow from operations; 8 in Euro; Source: boersengefluester.de
Auditor: KPMG
All relevant valuation ratios, dates and other investor information on your share at a glance. Good to know: All data comes from boersengefluester.de and is updated daily. This means you are always up to date. You can get brief explanations of the key figures by moving the cursor or mouse over the relevant field.
| INVESTOR-INFORMATION | ||||||
| ©boersengefluester.de | ||||||
| CompuGroup Medical | ||||||
| WKN | ISIN | Legal Type | Marketcap | IPO | Recommendation | Plus Code |
| A28890 | DE000A288904 | SE & Co. KGaA | 1.499,20 Mio € | 04.05.2007 | Halten | 9F299HQG+3H |
| PE 2027e | PE 10Y-Ø | BGFL-Ratio | Shiller-PE | PB | PCF | KUV |
| 19,93 | 31,06 | 0,64 | 24,28 | 2,41 | 11,63 | 1,30 |
|
Dividend '2023 in € |
Dividend '2024 in € |
Dividend '2025e in € |
Div.-Yield '2025e in % |
| 1,00 | 0,05 | 0,50 | 1,84% |
| Annual General Meeting | Q1-figures | Q2-figures | Q3-figures | Annual press conference |
| 17.04.2026 | 30.04.2025 | 31.07.2025 | 07.11.2024 | 06.03.2025 |
| Distance 60-days-line | Distance 200-days-line | Performance YtD | Performance 52 weeks | IPO |
| +2,82% | +8,73% | +6,55% | +23,52% | +50,83% |
Founded in 2013 by Gereon Kruse, the financial portal boersengefluester.de is all about German shares - with a clear focus on second-line stocks. In addition to traditional editorial articles, the site stands out in particular thanks to a large number of self-developed analysis tools. All tools are based on a completely self-maintained database for more than 650 shares. As a result, boersengefluester.de produces Germany's largest profit and dividend forecast.